| Gene symbol | CEACAM5 | Synonyms | CD66e, CEA | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.2 | dbXrefs | |
| Description | CEA cell adhesion molecule 5 | ||||
| GTO ID | GTC3338 |
| Trial ID | NCT05736731 |
| Disease | Pancreatic Cancer | Lung Non-Squamous Non-Small Cell Carcinoma | Lung Non-Small Cell Carcinoma | Colorectal Cancer | Colorectal Adenocarcinoma |
| Altered gene | CEA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | A2B530 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression |
| Year | 2023 |
| Country | United States |
| Company sponsor | A2 Biotherapeutics Inc. |
| Other ID(s) | A2B530-101 |
| Cohort 1 | |||||||||||
|
|||||||||||